Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Brain Research

• Publication date

  2007-12-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.BRAINRES.2007.09.034PMID 17963733PMCID PMC2265207
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The insulin-like growth factor system in multiple sclerosis.

  2007cited by this paper
• Sexual dimorphism in disease onset and progression of a rat model of ALS

  2007cited by this paper
• Adeno-associated viral-mediated insulin-like growth factor delivery protects motor neurons in vitro

  2007cited by this paper
• Interaction between interferon γ and insulin‐like growth factor‐1 in hippocampus impacts on the ability of rats to sustain long‐term potentiation

  2006cited by this paper
• 1062. Intracerebellar Injection of AAV-IGF-1 Improves Motor Function and Extends Survival in a Mouse Model of Amyotrophic Lateral Sclerosis

  2006cited by this paper
• Gene‐based treatment of motor neuron diseases

  2006cited by this paper
• Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia

  2006cited by this paper
• Loss of the astrocyte glutamate transporter GLT1 modifies disease in SOD1(G93A) mice.

  2006cited by this paper
• Statin Use and Sex-Specific Stroke Outcomes in Patients With Vascular Disease

  2006cited by this paper
• Disease progression of human SOD1 (G93A) transgenic ALS model rats

  2006cited by this paper
• Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis

  2005cited by this paper
• Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model

  2005cited by this paper
• Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model

  2005cited by this paper
• Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of Amyotrophic Lateral Sclerosis.

  2005cited by this paper
• Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS.

  2005cited by this paper
• Synergy of insulin‐like growth factor‐1 and exercise in amyotrophic lateral sclerosis

  2005cited by this paper
• Insulin-like growth factor system in amyotrophic lateral sclerosis.

  2005cited by this paper
• Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS

  2005cited by this paper
• Prevention of spinal motor neuron death by insulin‐like growth factor‐1 associating with the signal transduction systems in SODG93A transgenic mice

  2005cited by this paper
• Signaling by insulin-like growth factor 1 in brain.

  2004cited by this paper
• Role of insulin-like growth factor I signaling in neurodegenerative diseases

  2004cited by this paper
• VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model

  2004cited by this paper
• Gene therapy for ALS delivers.

  2004cited by this paper
• IGF-I prevents glutamate-induced motor neuron programmed cell death.

  2004cited by this paper
• Unraveling the mechanisms involved in motor neuron degeneration in ALS.

  2004cited by this paper
• Recombinant AAV‐mediated gene delivery to the central nervous system

  2004cited by this paper
• Free insulin-like growth factor (IGF)-I and IGF binding proteins 2, 5, and 6 in spinal motor neurons in amyotrophic lateral sclerosis.

  2003cited by this paper
• Tetracycline-inducible transgene expression mediated by a single AAV vector

  2003cited by this paper
• From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy.

  2003cited by this paper
• Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model

  2003cited by this paper
• Targeted Expression of IGF‐1 Transgene to Skeletal Muscle Accelerates Muscle and Motor Neuron Regeneration

  2003cited by this paper
• Sexual differences in onset of disease and response to exercise in a transgenic model of ALS.

  2003cited by this paper
• Single HSV-amplicon vector mediates drug-induced gene expression via dimerizer system.

  2003cited by this paper
• Rescue of rat spinal motoneurons from avulsion-induced cell death by intrathecal administration of IGF-I and Cerebrolysin.

  2003cited by this paper
• Neuroprotective Effects of Glial Cell Line-Derived Neurotrophic Factor Mediated by an Adeno-Associated Virus Vector in a Transgenic Animal Model of Amyotrophic Lateral Sclerosis

  2002cited by this paper
• Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS)

  2002cited by this paper
• Increased Survival and Function of SOD1 Mice After Glial Cell-Derived Neurotrophic Factor Gene Therapy

  2002influential reference
• Protective effects of cardiotrophin-1 adenoviral gene transfer on neuromuscular degeneration in transgenic ALS mice.

  2001cited by this paper
• Motoneuron cell death and neurotrophic factors: Basic models for development of new therapeutic strategies in ALS

  2001cited by this paper
• Insulin-like growth factor 1 prevents neuronal cell death and paraplegia in the rabbit model of spinal cord ischemia.

  2001cited by this paper
• Rats Expressing Human Cytosolic Copper–Zinc Superoxide Dismutase Transgenes with Amyotrophic Lateral Sclerosis: Associated Mutations Develop Motor Neuron Disease

  2001cited by this paper
• Delayed application of IGF-I and GDNF can rescue already injured postnatal motor neurons

  2001cited by this paper
• Gene Therapy for Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases

  2000cited by this paper
• Increased motoneuron survival and improved neuromuscular function in transgenic ALS mice after intraspinal injection of an adeno-associated virus encoding Bcl-2.

  2000cited by this paper
• Long-Term rAAV-Mediated Gene Transfer of GDNF in the Rat Parkinson's Model: Intrastriatal But Not Intranigral Transduction Promotes Functional Regeneration in the Lesioned Nigrostriatal System

  2000cited by this paper
• A controlled trial of recombinant methionyl human BDNF in ALS

  1999cited by this paper
• Preclinical testing of neuroprotective neurotrophic factors in a model of chronic motor neuron degeneration.

  1999cited by this paper
• A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis

  1998influential reference
• A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group.

  1998cited by this paper
• Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors

  1997cited by this paper
• Topical application of insulin like growth factor-1 reduces edema and upregulation of neuronal nitric oxide synthase following trauma to the rat spinal cord.

  1997cited by this paper
• ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions.

  1997cited by this paper
• Rediscovering an old friend, IGF-I: potential use in the treatment of neurodegenerative diseases.

  1997cited by this paper
• Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group.

  1997cited by this paper
• A double‐blind placebo‐controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis

  1996cited by this paper
• Intrathecal delivery of CNTF using encapsulated genetically modifiedxenogeneic cells in amyotrophic lateral sclerosis patients

  1996influential reference
• An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria.

  1995cited by this paper
• Beneficial effects of insulin-like growth factor-I on wobbler mouse motoneuron disease.

  1995cited by this paper
• Neurotrophic agents prevent motoneuron death following sciatic nerve section in the neonatal mouse.

  1994cited by this paper
• Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation.

  1994cited by this paper
• Insulin-like growth factor-I: potential for treatment of motor neuronal disorders.

  1993cited by this paper
• Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.

  1993cited by this paper
• Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

  1993cited by this paper
• Survival effect of ciliary neurotrophic factor (CNTF) on chick embryonic motoneurons in culture: comparison with other neurotrophic factors and cytokines

  1990cited by this paper

• AAV-mediated BDNF and GAS6 muscle delivery delays disease onset in SOD1G93A ALS mice.

  2025cites this paper
• Targeting Amyotrophic Lateral Sclerosis with Gene Therapy: From Silencing Genes to Enhancing Neuroprotection

  2025influential citation
• Applications of Focused Ultrasound for Spinal Disorders and Beyond: Advances and Future Prospects – A Narrative Review

  2025cites this paper
• Learning From the Exception and Not the Rule: Genetic Associations With an Amyotrophic Lateral Sclerosis Reversal Phenotype.

  2024cites this paper
• Genetic Associations With an Amyotrophic Lateral Sclerosis Reversal Phenotype

  2024cites this paper
• EphrinB2 knockdown in cervical spinal cord preserves diaphragm innervation in a mutant SOD1 mouse model of ALS

  2024influential citation
• Exploring P2X7 receptor antagonism as a therapeutic target for neuroprotection in an hiPSC motor neuron model

  2024cites this paper
• Growth factors and molecular-driven plasticity in neurological systems.

  2023cites this paper
• Neurotrophic Factors as Regenerative Therapy for Neurodegenerative Diseases: Current Status, Challenges and Future Perspectives

  2023cites this paper
• Current State and Future Directions in the Therapy of ALS

  2023cites this paper
• Pegylated Insulin-Like Growth Factor 1 attenuates Hair Cell Loss and promotes Presynaptic Maintenance of Medial Olivocochlear Cholinergic Fibers in the Cochlea of the Progressive Motor Neuropathy Mouse

  2022cites this paper
• Dendrimer-2PMPA Delays Muscle Function Loss and Denervation in a Murine Model of Amyotrophic Lateral Sclerosis

  2022cites this paper
• Dysregulation of IGF-1/GLP-1 signaling in the progression of ALS: potential target activators and influences on neurological dysfunctions

  2021cites this paper
• Applications of Adeno-Associated Virus Vector-Mediated Gene Delivery for Neurodegenerative Diseases and Psychiatric Diseases: Progress, Advances, and Challenges.

  2021cites this paper
• Neurotrophic Therapy for ALS/MND

  2021cites this paper
• An Approach to Maximize Retrograde Transport Based on the Spatial Distribution of Motor Endplates in Mouse Hindlimb Muscles

  2021cites this paper
• Overcoming the blood-brain barrier in neurodegenerative disorders and brain tumours.

  2020cites this paper
• Beyond the Traditional Clinical Trials for Amyotrophic Lateral Sclerosis and The Future Impact of Gene Therapy

  2020cites this paper
• OMICS-BASED EXPLORATION AND FUNCTIONAL VALIDATION OF NEUROTROPHIC FACTORS AND HISTAMINE AS THERAPEUTIC TARGETS IN ALS.

  2020cites this paper
• Intracisternal IGF‐1 gene therapy abrogates kainic acid‐induced excitotoxic damage of the rat spinal cord

  2020cites this paper
• What do we know about the variability in survival of patients with amyotrophic lateral sclerosis?

  2020cites this paper
• Peripheral and Central Nervous System Immune Response Crosstalk in Amyotrophic Lateral Sclerosis

  2020cites this paper
• Insulin-like growth factor 1 signaling in motor neuron and polyglutamine diseases: From molecular pathogenesis to therapeutic perspectives.

  2020cites this paper
• Association of Insulin-like Growth Factor 1 Concentrations with Risk for and Prognosis of Amyotrophic Lateral Sclerosis – Results from the ALS Registry Swabia

  2020cites this paper
• Focal and dose-dependent neuroprotection in ALS mice following AAV2-neurturin delivery.

  2020cites this paper
• The Role of Insulin-Like Growth Factors and Insulin-Like Growth Factor–Binding Proteins in the Nervous System

  2019cites this paper
• Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates

  2019cites this paper
• Gene Therapy for ALS—A Perspective

  2019cites this paper
• Targeted intraspinal injections to assess therapies in rodent models of neurological disorders

  2019cites this paper
• The role of Insulin-like Growth Factors (IGFs) and IGF-binding proteins in the nervous system

  2019cites this paper
• AAV gene delivery to the spinal cord: serotypes, methods, candidate diseases, and clinical trials

  2018cites this paper
• Effects of an Intraparenchymal Injection of Lidocaine in the Rat Cervical Spinal Cord

  2018cites this paper
• Systemic administration of scAAV9-IGF1 extends survival in SOD1G93A ALS mice via inhibiting p38 MAPK and the JNK-mediated apoptosis pathway.

  2018cites this paper
• RNS60 exerts therapeutic effects in the SOD1 ALS mouse model through protective glia and peripheral nerve rescue

  2018cites this paper
• IGF1 affects macrophage invasion and activation and TNF-α production in the sciatic nerves of female SOD1G93A mice.

  2018cites this paper
• Gene Therapy for Amyotrophic Lateral Sclerosis

  2017cites this paper
• Motor Neuron Gene Therapy: Lessons from Spinal Muscular Atrophy for Amyotrophic Lateral Sclerosis

  2017cites this paper
• Modélisation et analyses physiopathologiques de la Sclérose Latérale Amyotrophique liée à l'ubiquiline 2 à l'aide de vecteurs AAV10

  2017cites this paper
• Drug and Gene Delivery to the Central Nervous System for Neuroprotection

  2017cites this paper
• Vitamin D and Neurological Diseases: An Endocrine View

  2017cites this paper
• Multiple intracerebroventricular injections of human umbilical cord mesenchymal stem cells delay motor neurons loss but not disease progression of SOD1G93A mice.

  2017cites this paper
• Viral Vector Gene Delivery to the Brain for Treating Neurogenetic Diseases

  2017cites this paper
• Neuroprotection As a Therapeutic Approach for Spinal Muscular Atrophy

  2017cites this paper
• α CAR IGF‐1 vector targeting of motor neurons ameliorates disease progression in ALS mice

  2016cites this paper
• Brain-Derived Neurotrophic Factor Facilitates Functional Recovery from ALS-Cerebral Spinal Fluid-Induced Neurodegenerative Changes in the NSC-34 Motor Neuron Cell Line

  2016cites this paper
• Potential new complication in drug therapy development for amyotrophic lateral sclerosis

  2016cites this paper
• Gene Therapy for the Treatment of Neurological Disorders: Amyotrophic Lateral Sclerosis.

  2016cites this paper
• β2-Adrenoceptor agonists as novel, safe and potentially effective therapies for Amyotrophic lateral sclerosis (ALS).

  2016cites this paper
• Adeno-Associated Virus-Based Gene Therapy for CNS Diseases

  2016cites this paper
• Intrathecal Delivery of ssAAV9-DAO Extends Survival in SOD1G93A ALS Mice

  2016cites this paper
• Therapeutic progress in amyotrophic lateral sclerosis-beginning to learning.

  2016cites this paper
• MicroNeurotrophins Improve Survival in Motor Neuron-Astrocyte Co-Cultures but Do Not Improve Disease Phenotypes in a Mutant SOD1 Mouse Model of Amyotrophic Lateral Sclerosis

  2016cites this paper
• Connexin 43 in astrocytes contributes to motor neuron toxicity in amyotrophic lateral sclerosis

  2016cites this paper
• Trophic Factors in the Therapeutic Challenge Against ALS: Current Research Directions

  2016cites this paper
• Current developments in gene therapy for amyotrophic lateral sclerosis

  2015cites this paper
• Gene delivery to the spinal cord using MRI-guided focused ultrasound

  2015cites this paper
• Sponge-mediated lentivirus delivery to acute and chronic spinal cord injuries.

  2015cites this paper
• Administration of insulin-like growth factor-1 inhibits the overdevelopment of chloroquine-induced vacuoles in muscle fibers in experimental rimmed vacuolar myopathy

  2015cites this paper
• GLT1 overexpression in SOD1(G93A) mouse cervical spinal cord does not preserve diaphragm function or extend disease.

  2015cites this paper
• Intramuscular Injections Along the Motor End Plates: A Minimally Invasive Approach to Shuttle Tracers Directly into Motor Neurons.

  2015cites this paper
• Polyethylene glycol-coupled IGF1 delays motor function defects in a mouse model of spinal muscular atrophy with respiratory distress type 1.

  2014cites this paper
• Trophic Factor Production by Glial Cells in the Treatment of Amyotrophic Lateral Sclerosis

  2014cites this paper
• Gene therapy and cell reprogramming for the aging brain: achievements and promise.

  2014cites this paper
• The role of complement system in amyotrophic lateral sclerosis

  2014cites this paper
• Antioxidant gene therapy against neuronal cell death.

  2014cites this paper
• Translating biological findings into new treatment strategies for amyotrophic lateral sclerosis (ALS).

  2014cites this paper
• Application of Viral Vectors to Motor Neuron Disorders

  2014cites this paper
• Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis

  2013cites this paper
• Immune-mediated Mechanisms in the Pathoprogression of Amyotrophic Lateral Sclerosis

  2013cites this paper
• Growth hormone secretion is correlated with neuromuscular innervation rather than motor neuron number in early-symptomatic male amyotrophic lateral sclerosis mice.

  2013cites this paper
• Gene Therapy for Amyotrophic Lateral Sclerosis

  2013cites this paper
• Recent Advances in ALS Research: Perspectives for Personalized Clinical Application

  2013influential citation
• of amyotrophic lateral sclerosis

  2013cites this paper
• Amyotrophic lateral sclerosis: new insights into underlying molecular mechanisms and opportunities for therapeutic intervention.

  2012cites this paper
• Ablation of Proliferating Cells in the CNS Exacerbates Motor Neuron Disease Caused by Mutant Superoxide Dismutase

  2012cites this paper
• Functional improvement in mouse models of familial amyotrophic lateral sclerosis by PEGylated insulin-like growth factor I treatment depends on disease severity

  2012cites this paper
• Research advances in gene therapy approaches for the treatment of amyotrophic lateral sclerosis

  2012cites this paper
• Neuroprotection for amyotrophic lateral sclerosis: role of stem cells, growth factors, and gene therapy.

  2012cites this paper
• Gene therapy for amyotrophic lateral sclerosis.

  2012cites this paper
• Potential for promoting recurrent laryngeal nerve regeneration by remote delivery of viral gene therapy

  2012cites this paper
• Gene Therapy for Motor Neuron Disease

  2011cites this paper
• Intraspinal cell transplantation for targeting cervical ventral horn in amyotrophic lateral sclerosis and traumatic spinal cord injury.

  2011cites this paper
• Can vitamin D delay the progression of ALS?

  2011cites this paper
• Motor neuron trophic factors: therapeutic use in ALS?

  2011cites this paper
• Genetic strategies to study TDP‐43 in rodents and to develop preclinical therapeutics for amyotrophic lateral sclerosis

  2011cites this paper
• Relationship between neuropathology and disease progression in the SOD1(G93A) ALS mouse.

  2011cites this paper
• Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs

  2011cites this paper
• Harmine, a natural beta-carboline alkaloid, upregulates astroglial glutamate transporter expression.

  2011cites this paper
• CNS-targeted viral delivery of G-CSF in an animal model for ALS: improved efficacy and preservation of the neuromuscular unit.

  2011cites this paper
• Gene therapy for the peripheral nervous system: a strategy to repair the injured nerve?

  2011cites this paper
• Restorative effect of intracerebroventricular insulin-like growth factor-I gene therapy on motor performance in aging rats.

  2011cites this paper
• Therapeutic effects of PEGylated insulin-like growth factor I in the pmn mouse model of motoneuron disease.

  2011cites this paper
• Human Glial-Restricted Progenitor Transplantation into Cervical Spinal Cord of the SOD1G93A Mouse Model of ALS

  2011cites this paper
• Combination of SMN Trans-Splicing and a Neurotrophic Factor Increases the Life Span and Body Mass in a Severe Model of Spinal Muscular Atrophy

  2011cites this paper
• Trans-Splicing, More Than Meets the Eye: Multifaceted Therapeutics for Spinal Muscular Atrophy

  2011cites this paper
• Motor neuron–immune interactions: the vicious circle of ALS

  2010cites this paper
• Therapeutic Effect of the Combined Use of Growth Hormone Releasing Peptide-6 and Epidermal Growth Factor in an Axonopathy Model

  2010cites this paper
• Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.

  2010cites this paper
• Recent advances in amyotrophic lateral sclerosis research: perspectives for personalized clinical application

  2010cites this paper
• AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice.

  2010cites this paper